Abstract LB054: Confirmation of target inhibition and anti-tumor activity of the SHP2 inhibitor RMC-4630 via longitudinal analysis of ctDNA in a phase 1 clinical study
Year: 2021
Type: conference-abstract
Source: Cancer Research
Authors: Josie L. Hayes, Marianna Koczywas, Sai-Hong Ignatius Ou, Pasi A. Janne, Jose M. Pacheco, Susanna Ulahannan, Judy S. Wang, Howard A. Burris, Jonathan W. Riess, Caroline McCoach, Michael S. Gordon, Anna Capasso, Ariel Chen, Richa Dua, Bojena Bitman, Martha Guerra, Hongfang Wang, Xiaolin Wang, Eric Haura
Institutions: Revolution Medicines (United States), City Of Hope National Medical Center, University of California, Irvine, Dana-Farber Cancer Institute, University of Colorado Denver, University of Oklahoma, Sarah Cannon, Tennessee Oncology, University of California, Davis, University of California, San Francisco, HonorHealth, The University of Texas at Austin, Moffitt Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3181973044